Psychometric evaluation of a new handicap scale in immune-mediated polyneuropathies
Psychometric evaluation of a new handicap scale in immune-mediated polyneuropathies
复制标题
DOI：
10.1002/mus.10045
复制
发表时间：
2002-03-01
期刊：
影响因子：
3.4
通讯作者：
van Doorn, PA
中科院分区：
文献类型：
--
作者：
Merkies, ISJ;Schmitz, PIM;van Doorn, PA
开发了一种新的障碍测量方法——鹿特丹九项障碍量表，并在免疫介导的多发性神经病患者中评估了其有效性、可靠性和反应性。我们评估了 113 名病情稳定的患者，其中 83 名患有吉兰-巴利综合征 (GBS)，22 名患有慢性炎症性脱髓鞘性多发性神经病 (CIDP)，8 名患有丙种球蛋白病相关的多发性神经病。我们还研究了 20 名最近诊断为 GBS (n = 7) 或 CIDP (n = 13) 且临床状况发生变化的患者（纵向组）。鹿特丹九项障碍量表证明了与Rankin量表的显着区分效度和相关性（稳定组：斯皮尔曼检验，r = -76至-.78；纵向组：组内相关系数，r = .83；P < .0001）。此外，鹿特丹九项障碍量表还获得了良好的可靠性（r = .89-.98；P < .0001）和高响应值（标准化响应平均值 > .8）。与兰金量表相反，鹿特丹量表不仅提供有关流动性的信息，还强调身体独立、职业和社会融合。这些结果说明了鹿特丹九项障碍量表在这些条件下的临床实用性。 (C) 2002 年 Wiley 期刊公司
A new handicap measure, the Rotterdam nine-item handicap scale, was developed and its validity, reliability, and responsiveness evaluated in patients with immune-mediated polyneuropathies. We evaluated 113 stable patients, of whom 83 had Guillain-Barre syndrome (GBS), 22 had chronic inflammatory demyelinating polyneuropathy (CIDP), and 8 had a gammopathy-related polyneuropathy. We also studied 20 patients with recently diagnosed GBS (n = 7) or CIDP (n = 13) and changing clinical conditions (longitudinal group). Significant discriminatory validity and correlation with the Rankin scale were demonstrated for the Rotterdam nine-item handicap scale (stable group: Spearman's test, r = -76 to -.78; longitudinal group: intraclass correlation coefficient, r = .83; P < .0001). Also, good reliability (r = .89-.98; P < .0001) and high responsiveness values (standardized response mean values > .8) were obtained for the Rotterdam nine-item handicap scale. In contrast to the Rankin scale, the Rotterdam scale not only provided information regarding mobility but also highlighted physical independence, occupation, and social integration. These results illustrate the clinical usefulness of the Rotterdam nine-item handicap scale under these conditions. (C) 2002 Wiley Periodicals, Inc.